Mitomycin Cversus 5-fluorouracil as an adjunctive treatment for trabeculectomy: A meta-analysis of randomized clinical trials

Lígia I. De Fendi, Gustavo V. Arruda, Ingrid U. Scott, Jayter S. Paula

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Mitomycin C (MMC) and 5-fluorouracil (5-FU) are the most frequently utilized adjuvant therapies in trabeculectomy (TRAB), but there is no general consensus as to the direct comparative efficacy and safety of these two adjuvants. In this study, the authors conducted a meta-analysis to compare the efficacy and safety of augmenting TRAB with MMC or 5-FU. A systematic review with meta-analysis was conducted and five randomized controlled clinical trials comparing MMC versus 5-FU as adjunctive therapies were identified, totaling 416 participants. A lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. Epithelial corneal defects were the unique complication reported more frequently with 5-FU compared to MMC treatment. Compared to TRAB with 5-FU, TRAB with MMC was associated with higher rates of complete and qualified surgical success and was not associated with increased incidences of postoperative complications.

Original languageEnglish (US)
Pages (from-to)798-806
Number of pages9
JournalClinical and Experimental Ophthalmology
Volume41
Issue number8
DOIs
StatePublished - Apr 19 2013

Fingerprint

Trabeculectomy
Mitomycin
Fluorouracil
Meta-Analysis
Randomized Controlled Trials
Safety
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{81aa56a78cee4cfead7f14adaecdfa90,
title = "Mitomycin Cversus 5-fluorouracil as an adjunctive treatment for trabeculectomy: A meta-analysis of randomized clinical trials",
abstract = "Mitomycin C (MMC) and 5-fluorouracil (5-FU) are the most frequently utilized adjuvant therapies in trabeculectomy (TRAB), but there is no general consensus as to the direct comparative efficacy and safety of these two adjuvants. In this study, the authors conducted a meta-analysis to compare the efficacy and safety of augmenting TRAB with MMC or 5-FU. A systematic review with meta-analysis was conducted and five randomized controlled clinical trials comparing MMC versus 5-FU as adjunctive therapies were identified, totaling 416 participants. A lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. Epithelial corneal defects were the unique complication reported more frequently with 5-FU compared to MMC treatment. Compared to TRAB with 5-FU, TRAB with MMC was associated with higher rates of complete and qualified surgical success and was not associated with increased incidences of postoperative complications.",
author = "{De Fendi}, {L{\'i}gia I.} and Arruda, {Gustavo V.} and Scott, {Ingrid U.} and Paula, {Jayter S.}",
year = "2013",
month = "4",
day = "19",
doi = "10.1111/ceo.12097",
language = "English (US)",
volume = "41",
pages = "798--806",
journal = "Clinical and Experimental Ophthalmology",
issn = "1442-6404",
publisher = "Wiley-Blackwell",
number = "8",

}

Mitomycin Cversus 5-fluorouracil as an adjunctive treatment for trabeculectomy : A meta-analysis of randomized clinical trials. / De Fendi, Lígia I.; Arruda, Gustavo V.; Scott, Ingrid U.; Paula, Jayter S.

In: Clinical and Experimental Ophthalmology, Vol. 41, No. 8, 19.04.2013, p. 798-806.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mitomycin Cversus 5-fluorouracil as an adjunctive treatment for trabeculectomy

T2 - A meta-analysis of randomized clinical trials

AU - De Fendi, Lígia I.

AU - Arruda, Gustavo V.

AU - Scott, Ingrid U.

AU - Paula, Jayter S.

PY - 2013/4/19

Y1 - 2013/4/19

N2 - Mitomycin C (MMC) and 5-fluorouracil (5-FU) are the most frequently utilized adjuvant therapies in trabeculectomy (TRAB), but there is no general consensus as to the direct comparative efficacy and safety of these two adjuvants. In this study, the authors conducted a meta-analysis to compare the efficacy and safety of augmenting TRAB with MMC or 5-FU. A systematic review with meta-analysis was conducted and five randomized controlled clinical trials comparing MMC versus 5-FU as adjunctive therapies were identified, totaling 416 participants. A lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. Epithelial corneal defects were the unique complication reported more frequently with 5-FU compared to MMC treatment. Compared to TRAB with 5-FU, TRAB with MMC was associated with higher rates of complete and qualified surgical success and was not associated with increased incidences of postoperative complications.

AB - Mitomycin C (MMC) and 5-fluorouracil (5-FU) are the most frequently utilized adjuvant therapies in trabeculectomy (TRAB), but there is no general consensus as to the direct comparative efficacy and safety of these two adjuvants. In this study, the authors conducted a meta-analysis to compare the efficacy and safety of augmenting TRAB with MMC or 5-FU. A systematic review with meta-analysis was conducted and five randomized controlled clinical trials comparing MMC versus 5-FU as adjunctive therapies were identified, totaling 416 participants. A lower pooled mean IOP and higher complete and qualified success rates were observed in the MMC arm than in the 5-FU arm. Epithelial corneal defects were the unique complication reported more frequently with 5-FU compared to MMC treatment. Compared to TRAB with 5-FU, TRAB with MMC was associated with higher rates of complete and qualified surgical success and was not associated with increased incidences of postoperative complications.

UR - http://www.scopus.com/inward/record.url?scp=84886306684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886306684&partnerID=8YFLogxK

U2 - 10.1111/ceo.12097

DO - 10.1111/ceo.12097

M3 - Article

C2 - 24308066

AN - SCOPUS:84886306684

VL - 41

SP - 798

EP - 806

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

SN - 1442-6404

IS - 8

ER -